Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 632 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

NCT07044479
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

NCT07412288
View directory record Official record
Conditions
Healthy Participants
Interventions
KT-579, Placebo
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

NCT06649877
View directory record Official record
Conditions
Healthy
Interventions
MK-6194
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults

NCT06670170
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-07976016 Formulation A, PF-07976016 Formulation B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants

NCT01800682
View directory record Official record
Conditions
Healthy
Interventions
Tramodol Extended-Release (ER)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jul 22, 2026, 11:10 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642
View directory record Official record
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)

NCT06662396
View directory record Official record
Conditions
Healthy
Interventions
MK-6552, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

NCT07118215
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, Midazolam, Fexofenadine, Digoxin
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

NCT06813924
View directory record Official record
Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

NCT01571960
View directory record Official record
Conditions
HIV Infections
Interventions
GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

NCT00083603
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT), rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT), Empty TBC-FPV, TBC-MVA and TBC-FPV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 22, 2026, 11:10 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

NCT07226882
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 44 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
6
States / cities
Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

NCT02570074
View directory record Official record
Conditions
Healthy Subjects
Interventions
Fosfomycin
Drug
Lead sponsor
Vance Fowler, M.D.
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

NCT05686980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Anaheim, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)

NCT06903715
View directory record Official record
Conditions
Healthy
Interventions
Belzutifan, Phenytoin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

NCT03586843
View directory record Official record
Conditions
Obesity
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 22, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants

NCT06909162
View directory record Official record
Conditions
Healthy Participants
Interventions
INCB123667, itraconazole, carbamazepine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
19 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 11:10 PM EDT